Aminopeptidase Inhibition in Drug-Resistant Plasmodium falciparum: Structural, Functional, and Pharmacological...

Area of Science:

• Parasitology
• Drug Discovery
• Structural Biology

Background:

• Malaria, caused by Plasmodium falciparum, is a major global health issue.
• Emerging drug resistance, particularly to artemisinins, necessitates novel therapeutic strategies.
• Hemoglobin digestion by PfA-M1 and PfA-M17 is crucial for parasite survival within red blood cells.

Purpose of the Study:

• To review the evidence supporting PfA-M17 and PfA-M1 as antimalarial drug targets.
• To highlight the structural biology, regulation, and essentiality of PfA-M17.
• To explore the potential of dual PfA-M1/PfA-M17 inhibition for malaria treatment.

Main Methods:

• Literature review synthesizing current evidence on PfA-M1 and PfA-M17.
• Analysis of structural biology and catalytic regulation mechanisms.
• Evaluation of selective and dual-target inhibitors and their efficacy.

Main Results:

• PfA-M17 activation via oligomerization and a regulatory loop (L13) presents potential constraints on resistance.
• Selective and dual inhibitors (e.g., MMV1557817, compound 26) show antiplasmodial activity and impose fitness costs on resistant parasites.
• Mechanistic interplay between aminopeptidase inhibition and existing antimalarials (quinolines, artemisinins) is examined.

Conclusions:

• PfA-M17 and PfA-M1 are validated antimalarial targets.
• Dual inhibition of PfA-M1 and PfA-M17 is a promising strategy for developing next-generation antimalarials.
• Targeting these metalloaminopeptidases may overcome current drug resistance challenges.